A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2018
Price : $35 *
At a glance
- Drugs RXI 109 (Primary)
- Indications Keloids
- Focus Therapeutic Use
- Sponsors Phio Pharmaceuticals; RXi Pharmaceuticals
- 13 Jun 2016 Status changed from active, no longer recruiting to completed.
- 25 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
- 25 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Oct 2015, as reported by ClinicalTrials.gov.